相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Peroxisome proliferator-activated receptor translational research and clinical experience
Wayman Wendell Cheatham
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Structure and Function of HDL Mimetics
Mohamad Navab et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans
Ashish Shah et al.
ATHEROSCLEROSIS (2010)
PCSK9 as a Therapeutic Target in Atherosclerosis
Ali J. Marian
Current Atherosclerosis Reports (2010)
A1C Between 5.7 and 6.4% as a Marker for Identifying Pre-Diabetes, Insulin Sensitivity and Secretion, and Cardiovascular Risk Factors The Insulin Resistance Atherosclerosis Study (IRAS)
Carlos Lorenzo et al.
DIABETES CARE (2010)
Postchallenge Glucose, A1C, and Fasting Glucose as Predictors of Type 2 Diabetes and Cardiovascular Disease A 10-year prospective cohort study
Henna Cederberg et al.
DIABETES CARE (2010)
Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
K. Kondo et al.
DIABETES OBESITY & METABOLISM (2010)
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2010)
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Philip J. Barter et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Does Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials
Pierluigi Costanzo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Cardiovascular effects of marine omega-3 fatty acids
Palaniappan Saravanan et al.
LANCET (2010)
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Paul W. Ladenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
Emily Y. Chew et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Regulatory enzymes of mitochondrial β-oxidation as targets for treatment of the metabolic syndrome
M. Schreurs et al.
OBESITY REVIEWS (2010)
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2009)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
Christopher J. Duff et al.
BIOCHEMICAL JOURNAL (2009)
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Rajesh Krishna et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacologic Inhibition of Squalene Synthase and Other Downstream Enzymes of the Cholesterol Synthesis Pathway A New Therapeutic Approach to Treatment of Hypercholesterolemia
Stephanie Seiki et al.
CARDIOLOGY IN REVIEW (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Apolipoprotein A-I Mimetic Peptides
Brian J. Van Lenten et al.
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
J. C. Ansquer et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Future Challenges for Microsomal Transport Protein Inhibitors
Anthony S. Wierzbicki et al.
CURRENT VASCULAR PHARMACOLOGY (2009)
Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
Xiao Hu et al.
ENDOCRINOLOGY (2009)
Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
Evan A. Stein
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2009)
Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
Heinz Drexel
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2009)
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
Marianne Abifadel et al.
HUMAN MUTATION (2009)
The mechanism and mitigation of niacin-induced flushing
V. S. Kamanna et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Alejandra Meaney et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults
Rita F. Redberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Allen J. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Frank Hermann et al.
THROMBOSIS RESEARCH (2009)
The safety of niacin in the US Food and Drug Administration Adverse Event Reporting database
Alawi A. Alsheikh-Ali et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins
Karim El Harchaoui et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2008)
Recommendations for the use of LDL apheresis
G. R. Thompson
ATHEROSCLEROSIS (2008)
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
M. J. Forrest et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Menno Vergeer et al.
CIRCULATION (2008)
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Stephen J. Nicholls et al.
CIRCULATION (2008)
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia
E. S. Nakou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia
M. Florentin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Multiple actions of high-density lipoprotein
Matilda Florentin et al.
CURRENT OPINION IN CARDIOLOGY (2008)
Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism
M. Mahmood Hussain et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
M. Elisaf et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality
Evangelos N. Liberopoulos et al.
EXPERT OPINION ON DRUG SAFETY (2008)
An overview of the extra-lipid effects of rosuvastatin
Michael S. Kostapanos et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2008)
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL
Lin-Hua Zhang et al.
JOURNAL OF LIPID RESEARCH (2008)
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
Jerome L. Fleg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Luigi Tavazzi et al.
LANCET (2008)
Effects of niacin on glucose control in patients with dyslipidemia
Ronald B. Goldberg et al.
MAYO CLINIC PROCEEDINGS (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
Anne B. Rossebo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Spotlight on HDL-raising therapies:: insights from the torcetrapib trials
Anatol Kontush et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans
Anders Berkenstam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Ezetimibe-associated adverse effects: what the clinician needs to know
M. Florentin et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
High-density lipoprotein mimetics: Focus on synthetic high-density lipoprotein
Prediman K. Shah
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Correction of low HDL cholesterol to reduce cardiovascular risk:: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®)
A. Vogt et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Statin-associated adverse effects beyond muscle and liver toxicity
D. N. Kiortsis et al.
ATHEROSCLEROSIS (2007)
Increasing apoA-I production as a target for CHD risk reduction
Stefan P. J. Dullens et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin
Irene F. Gazi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
D. P. Mikhailidis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
Charles R. Harper et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Michiel L. Bots et al.
LANCET (2007)
Do statins have an antiarrhythmic activity?
M. S. Kostapanos et al.
CARDIOVASCULAR RESEARCH (2007)
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia
Michael S. Kostapanos et al.
CLINICAL THERAPEUTICS (2007)
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: A case--control analysis in EPIC-Norfolk
Wim A. van der Steeg et al.
ANNALS OF INTERNAL MEDICINE (2007)
Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia
James M. McKenney et al.
PHARMACOTHERAPY (2007)
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia
Mihalis Kalogirou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis -: A randomized controlled trial
Jean-Claude Tardif et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis - The METEOR trial
John R. Crouse et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Safety considerations with fibrate therapy
Michael H. Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Safety considerations with niacin therapy
John R. Guyton et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Marina Cuchel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Langerhans cells release prostaglandin D2 in response to nicotinic acid
Dominique Maciejewski-Lenoir et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study
Robert H. Knopp et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview
Irene F. Gazi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
Michael H. Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
Allen J. Taylor et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
Harold Bays et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice
Lai Wang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia
Sridevi Devaraj et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Combination therapy with statins and omega-3 fatty acids
Vijay Nambi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Diet and lifestyle recommendations revision 2006 - A scientific statement from the American Heart Association Nutrition Committee (vol 114, pg 82, 2006)
Alice H. Lichtenstein et al.
CIRCULATION (2006)
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
Haralampos J. Milionis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Statins: another class of antihypertensive agents?
HJ Milionis et al.
JOURNAL OF HUMAN HYPERTENSION (2006)
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
HE Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia
RS Rosenson
ATHEROSCLEROSIS (2006)
Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis
A Tavridou et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of ACAT inhibition on the progression of coronary atherosclerosis
SE Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Antiatherogenic small, dense HDL - guardian angel of the arterial wall?
A Kontush et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2006)
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review
William Insull
SOUTHERN MEDICAL JOURNAL (2006)
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
SS Daskalopoulou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
DL Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Long-term effects of LDL apheresis in patients with severe hypercholesterolemia
BS Sachais et al.
JOURNAL OF CLINICAL APHERESIS (2005)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids - Results of the OmniHeart randomized trial
LJ Appel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
J McKenney et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
LA Carlson
JOURNAL OF INTERNAL MEDICINE (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reporting rate of Rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption
SW Altmann et al.
SCIENCE (2004)
Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy
RD Layne et al.
ANNALS OF PHARMACOTHERAPY (2004)
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
SH Ganji et al.
JOURNAL OF LIPID RESEARCH (2004)
Risk of adverse events with fibrates
AA Alsheikh-Ali et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial
JA de Lemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis
HR Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
AJ Taylor et al.
CIRCULATION (2004)
Molecular mediators of hepatic steatosis and liver injury
JD Browning et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7α-hydroxylase
H Li et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Effects of the acyl coenzyme A:: Cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions
JC Tardif et al.
CIRCULATION (2004)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Extended-released niacin for modifying the lipoprotein profile
JR Guyton
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Therapeutic potential of RNA interference
M Stevenson
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status
DG Hardie
ENDOCRINOLOGY (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
CE Chandler et al.
JOURNAL OF LIPID RESEARCH (2003)
Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435
BG Bhat et al.
JOURNAL OF LIPID RESEARCH (2003)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
DJ Rader et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
P Barter et al.
ATHEROSCLEROSIS (2003)
Niacin and cholesterol: role in cardiovascular disease (Review)
SH Ganji et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2003)
Insulin resistance and cardiovascular events with low HDL cholesterol - The Veterans Affairs HDL Intervention Trial (VA-HIT)
SJ Robins et al.
DIABETES CARE (2003)
Molecular identification of nicotinic acid receptor
T Soga et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis
LO Martinez et al.
NATURE (2003)
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
MM Hussain et al.
JOURNAL OF LIPID RESEARCH (2003)
SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs
KL West et al.
ATHEROSCLEROSIS (2003)
Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
HB Rubins et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
PM Kris-Etherton et al.
CIRCULATION (2002)
Inhibition of intestinal cholesterol absorption by ezetimibe in humans
T Sudhop et al.
CIRCULATION (2002)
Requirement for thyroid hormone receptor β in T3 regulation of cholesterol metabolism in mice
H Gullberg et al.
MOLECULAR ENDOCRINOLOGY (2002)
Bile acid regulation of gene expression: Roles of nuclear hormone receptors
JYL Chiang
ENDOCRINE REVIEWS (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
C Gagné et al.
CIRCULATION (2002)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia
T Sudhop et al.
DRUGS (2002)
Effects of fibrates on serum metabolic parameters
M Elisaf
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
BG Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
D Hunninghake et al.
ATHEROSCLEROSIS (2001)
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial
W Insull et al.
MAYO CLINIC PROCEEDINGS (2001)
Effects of monounsaturated enriched sunflower oil on CHD risk factors including LDL size and copper-induced LDL oxidation
EL Ashton et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2001)
Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality
YD Cui et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
HH Knapp et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Surgical management of dyslipidemia: Clinical and experimental evidence
MH Moghadasian et al.
JOURNAL OF INVESTIGATIVE SURGERY (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein
H Shinkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial
MB Elam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
G Alexandridis et al.
AMERICAN JOURNAL OF MEDICINE (2000)
ApoE polymorphism and fish oil supplementation in subjects with an antherogenic lipoprotein phenotype
AM Minihane et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly
DA Gordon et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2000)
Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass
M López-Santamaria et al.
JOURNAL OF PEDIATRIC SURGERY (2000)
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
A Goldberg et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Apolipoprotein B, a paradigm for proteins regulated by intracellular degradation, does not undergo intracellular degradation in CaCo2 cells
W Liao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species
T Ugawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
